Cambridge Innovation Capital

Cambridge Innovation Capital

Investing in technology and healthcare companies in the Cambridge Cluster.

Address: The Hauser Forum, 3 Charles Babbage Road, Cambridge
Postcode: CB3 0GT
Country: United Kingdom
Membership type:Corporate 6-20 (£250+VAT pa)

Cambridge Innovation Capital (“CIC”) invests in intellectual property rich companies in the Cambridge Cluster, combining a unique relationship with the University of Cambridge with deep financial and industry links to the area. The company strives to build leading businesses using a long term return strategy - removing the pressure to deliver the early exits associated with the traditional venture capital model.

CIC is led by an experienced investment team, an outstanding board and advisory panel of leading scientists and entrepreneurs, backed by long term institutional and strategic investors.

CIC has an unrivalled appreciation for world-leading scientific development given its position within the Cambridge Cluster. The company is committed to ensuring that its investment partners can build leading businesses from brilliant technologies - with the support of some of the most influential figures in the sector.

Andrew Williamson, Cambridge Innovation Capital

Origami Energy raises £18.6m series ‘B’ funding

Cambridge Innovation Capital (CIC) has participated in an £18.6 million funding round in Origami Energy. Aggreko plc, the FTSE-listed global leader in on-site power generation with a presence in over 100 countries, has made a major investment in this funding round. Other current investors also participated.

5 April 2018Read in full

CIC backs AI company Cytora

Cambridge Innovation Capital is backing AI insurance tech company Cytora as part of a £4.4 million funding round alongside a range of investors including insurance companies QBE and Starr.

7 December 2017Read in full

CIC supports the team

CIC leads £10m investment in, which offers improved AI for driverless cars

The big challenge for developers of autonomous vehicles is ensuring that they operate effectively in the real world. To tackle this and similar challenges, Cambridge start-up has raised £10 million in a series A funding round led by Cambridge Innovation Capital (CIC).

5 September 2017Read in full

Cambridge Innovation Capital highlights investments from its annual results

Cambridge Innovation Capital (CIC) announces highlights from its annual results for the year ended 31 March 2017.

6 July 2017Read in full

Bicycle Therapeutics, co-founded by blockbuster drug developer, raises £40m

The top blockbuster drug for 2016 was based on the techniques developed by Professor Sir Gregory Winter. Now his latest Cambridge company, Bicycle Therapeutics, has gained £40 million from investors including Cambridge Innovation Capital.

1 June 2017Read in full

Cambridge Innovation Capital provides a solution to the ‘scale-up chasm’ for start-ups

Cambridge Innovation Capital (CIC), a Cambridge-based investor in technology and healthcare companies, announces that its CEO, Victor Christou, will be presenting at the Global University Venturing: Fusion event in London this evening (Weds).

24 May 2017Read in full

Sapientia offers rapid diagnosis of rare disease

Cambridge Innovation Capital supports Congenica's international ambitions

Seventy-five per cent of patients with a rare disease are children. Cambridge-based Congenica has a world-leading technology that offers a rapid diagnosis. Already in clinical use in the UK, the company has raised £8 million to fund its international expansion.

27 February 2017Read in full

CIC appoints Dr Michael Anstey as Investment Director

CIC appoints Dr Michael Anstey as Investment Director

Cambridge Innovation Capital plc is pleased to announce the appointment of Dr Michael Anstey as an Investment Director specialising in healthcare investments.

31 January 2017Read in full

Mike Romanos, CEO of Microbiotica.

CIC and IP Group announce creation of Sanger Institute spinout with £8m funding

The creation of Microbiotica Ltd, a newly formed spin-out company from the UK’s Wellcome Trust Sanger Institute based at the Wellcome Genome Campus in Hinxton, Cambridge, has been announced by Cambridge Innovation Capital plc (CIC), a Cambridge-based investor in technology and healthcare companies, and IP Group plc, the developer of intellectual property-based businesses.

20 December 2016Read in full

Dr Andrew Williamson

Cambridge Innovation Capital appoints Dr Andrew Williamson as Investment Director

Cambridge Innovation Capital plc (CIC), a Cambridge-based investor in technology and healthcare companies, is pleased to announce the appointment of Dr Andrew Williamson as an Investment Director.

7 December 2016Read in full

  1. 1
  2. 2
  3. 3
  4. 4